Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_assertion type Assertion NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_head.
- NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_assertion description "[Hence, strategies that prevent GLP-1 degradation or activate the GLP-1 receptor are used to treat patients with type 2 diabetes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_provenance.
- NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_assertion evidence source_evidence_literature NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_provenance.
- NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_assertion SIO_000772 25412624 NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_provenance.
- NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_assertion wasDerivedFrom befree-2016 NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_provenance.
- NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_assertion wasGeneratedBy ECO_0000203 NP1238882.RAXLIaXA6mbgPkZWt_RlOJzNGhsX1cK7UW0jcnfGhf9Cw130_provenance.